pharmaphorum

DECEMBER 23, 2020

2020 also saw some of the first “tumour agnostic” cancer drugs get to market, with Bayer’s Vitravki (larotrectinib) getting funding in the UK for tumours with confirmed neurotrophic tyrosine receptor kinase (NTRK) gene fusions.”. The antibodies produced as a result lodge in the kidneys, causing severe complications.

Marketing 96

Marketing Gene Silencing Gene Drugs 96

Delveinsight

AUGUST 6, 2020

Hereditary ATTR amyloidosis , also known as Familial ATTR, is an autosomal dominant disease and a result of mutations in the TTR gene, thus it is passed down from one generation to the next one. The hATTR diagnosis is mainly dependent on symptoms and can be confirmed via performing tissue biopsies, genetic testing, and imaging studies.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

pharmaphorum

SEPTEMBER 1, 2021

. “The obvious disappointment is that they don’t seem to have thought it cost effective for familial hypercholesterolaemia (FH), where patients have genetically elevated LDL-C and limitations on treatments available. This needs further thought,” he added.

Drugs 98

Drugs Trials Gene Silencing Genetics 98

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. These therapeutics are broadly classified into two categories, namely coding RNAs and non-coding RNAs.

RNA 40

RNA Protein Genetics Gene Expression 40